R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Breelyn A. Wilky,Michelle A. Rudek,Shabina Ahmed,Daniel A. Laheru,David Cosgrove,Ross C. Donehower,Barry D. Nelkin,Douglas W. Ball,Lawrence A. Doyle,Helen X. Chen,Xiaobu Ye,G Bigley,Chris Womack,Nilo Azad +13 more
TL;DR: The study of anti-IGF-1R antibody cixutumumab and MEK 1/2 inhibitor selumetinib showed that the combination is safe and well-tolerated at these doses, with preliminary evidence of clinical benefit and pharmacodynamic evidence of target inhibition.
Journal Article
Prolonged Infusion of Hexamethylene Bisacetamide: A Phase I and Pharmacological Study
Eric K. Rowinsky,David S. Ettinger,William P. McGuire,Dennis A. Noe,Louise B. Grochow,Ross C. Donehower +5 more
TL;DR: It was apparent that the duration of HMBA exposure was an additional significant variable in predicting the magnitude of thrombocytopenia, and the maximum tolerated and recommended phase II doses for HMBA administered on this schedule were 20 and 15.8 g/m2/d, respectively.
Journal ArticleDOI
Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
TL;DR: Antitumor activity has been observed with topotecan and irinotican in patients with a variety of solid tumors and refractory leukemia in studies, which supports the widespread enthusiasm for this group of compounds.
Journal Article
Effects of rhGM-CSF on intracellular ara-C pharmacology in vitro in acute myelocytic leukemia: comparability with drug-induced humoral stimulatory activity.
TL;DR: Recombinant human granulocyte-macrophage colony stimulating factor acts similarly to HSA as an active stimulator of leukemic cell proliferation and net intracellular ara-C metabolism in vitro, and support clinical trials designed to examine the role of rhGM-CSF in enhancing aRA-C cytotoxicity by increasing the growth fraction of drug-responsive target cells in vivo.
Journal ArticleDOI
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer.
Mark Yarchoan,Chiung Yu Huang,Qingfeng Zhu,Anna Ferguson,Jennifer N. Durham,Robert A. Anders,Elizabeth D. Thompson,Noah Rozich,Dwayne L. Thomas,Julie M. Nauroth,Christina Rodriguez,Arsen Osipov,Ana De Jesus-Acosta,Dung T. Le,Adrian Murphy,Daniel A. Laheru,Ross C. Donehower,Elizabeth M. Jaffee,Lei Zheng,Nilofer S. Azad +19 more
TL;DR: Colon GVAX is an allogeneic, whole‐cell, granulocyte‐macrophage colony‐stimulating factor ‐secreting cellular immunotherapy that induces T‐cell immunity against tumor‐associated antigens and has previously been studied in combination with low‐dose cyclophosphamide (Cy) to inhibit regulatory T cells.